News from aidsmap

  • T-20 expanded access study announced

    Anna Poppa | 07 November 2001

    Roche have announced plans for widening access to their experimental fusion inhibitor, T-20 (pentafuside), a new type of anti-HIV treatment. A worldwide open-label safety study, codenamed T-20 305, is ...

  • Syphilis in HIV-positive gay Hamburgers

    Robert Fieldhouse | 30 October 2001

    One hundred years ago the German philosopher Friedrich Nietzsche lost his mental faculties as a result of tertiary syphilis infection. Today in the UK it is rare that the disease advances ...

  • Treating high cholesterol in HAART patients

    Keith Alcorn | 29 October 2001

    Controversy over the risk of heart disease in people on HAART continued at the Third International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Infection last week, with competing ...

  • Treatment of early hepatitis C prevents disease progression

    Robert Fieldhouse | 16 October 2001

    Researchers from the Medizinische Hochschule in Hannover, Germany in association with the clinic of infective diseases at the University of Bari, Italy have shown that treatment of acute hepatitis C ...

  • More tricky drug interactions: fine tuning HAART

    Keith Alcorn | 05 March 2001

    Highlights from the First International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands, March 30-31, 2000. Using efavirenz with bid IDV/RTV 800/100mg ABT-378/r with other PIs Amprenavir and ritonavir Amprenavir/ritonavir and efavirenz Saquinavir ...

  • US signals need for shorter salvage trials - but still out of step with Europe

    Keith Alcorn | 05 March 2001

    The US Food and Drug Administration has signalled that it is willing to move in the direction of shorter trials to license drugs for salvage therapy, following the lead of ...

  • Delavirdine setback in Europe

    Anon | 05 March 2001

    Pharmacia & Upjohn has been given the thumbs down for its NNRTI delavirdine (Rescriptor ,TM) by the CPMP, the scientific advisory committee of the European Medicines Evaluation Agency (EMEA). This ...

  • South African judge slams pharma cos in conference keynote speech

    Keith Alcorn | 05 March 2001

    Justice Edwin Cameron of South Africa’s High Court launched a blistering attack on pharmaceutical companies and his country’s government in a keynote address to the Thirteenth World AIDS Conference today ...

← Prev1...1314151617Next →

Editors’ picks from other sources

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.